Search Results

It’s the latest Big Pharma deal for molecular glue technology and Novartis’ second with Orionis Biosciences, after first linking up in March 2020. The backloaded agreement will see Novartis pay $40 million upfront.

Molecular Templates, Inc. today provided an update on its clinical-stage programs.

Degron Therapeutics will have stiff competition in immunology, as Novartis inked a $5.7 billion agreement with Monte Rosa Therapeutics last year to develop molecular glues for undisclosed immune-mediated conditions.

Molecular Templates, Inc. today provided an update on its programs.

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”) today reported financial results for the fourth quarter and full year ended December 31, 2023.

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action, today reported financial results and business updates for the first quarter of 2024.

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”) today reported financial results and business updates for the third quarter of 2023.